Researchers of the 52-week, phase 3 IXORA-Q trial looked to analyze general touch avoidance (TA) in patients who had moderate-to-severe genital psoriasis and were treated with ixekizumab. For 12 weeks, patients in the trial were given either 80 mg of ixekizumab every two weeks (N = 75) or placebo (N = 74), with all patients at Week 12 given 80 mg of ixekizumab every four weeks through Week 52. Patients had the chance to escalate dosing to once every two weeks at Weeks 24, 28, or 40. Using a numeric rating scale (NRS), patients self-reported TA degree over the previous 2 weeks. Most of the psoriasis outcomes assessed were parallel to the improvement in TA NRS score. Treatment with ixekizumab in patients with moderate-to-severe genital psoriasis was found to achieve sustained general TA improvement to Week 52.
Reference: Soung J, Cather JC, Gooderham M, et al. Improvement in general touch avoidance in patients with moderate-to-severe genital psoriasis treated with ixekizumab during a 52-week, randomized, phase 3 clinical trial (IXORA-Q). JEADV Clin Pract. 2023;1-11. doi:10.1002/jvc2.126
